Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt
Patent No. EP3995135 (titled "Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt") was filed by Grnenthal on Nov 10, 2020. The application was issued on Jul 13, 2022.
Patent Summary
Tablet providing a prolonged release of tapentadol, where tapentadol is in the form of a salt with tartaric acid, in particular L-(+)-tartaric acid. The tablet is made by applying a compressive force to a powder and consolidating the powder into a compacted form in the die of a press.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
EP3995135
- Application Number
- EP20206800A
- Filing Date
- Nov 10, 2020
- Status
- Granted And Under Opposition
- Jun 10, 2022
- Publication Date
- Jul 13, 2022
- External Links
- Slate, Register , Google Patents